Algert Global LLC increased its stake in Immunovant, Inc. (NASDAQ: IMVT) by 51.1% in the second quar

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

Shares of Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) reached a new 52-week high during mid-da

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Roivant said its first quarter was relatively quiet operationally but positioned the company for a m

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 thro

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst con

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' d

JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the

I initiate coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism aroun

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?

IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benef

Wall Street analysts changed outlook on top names. Guggenheim raised price target for IMVT, Piper Sa

Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the pric

Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newe

Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raise

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbust

Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.

Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&

Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence

B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and raises

HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and ra

Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a

Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expec

US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe&#39

Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst con

DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage imm

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it wil

Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) CTO Jay Stout sold 2,754 shares of Immunovant stoc

Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raise

Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other s

GSAT: 24% | Globalstar shares are trading higher following reports suggesting that Amazon is in disc

Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoin

HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and m

Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the pric

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.61) per share which beat the analyst conse

Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raise

Wolfe Research analyst Andy Chen upgrades Immunovant (NASDAQ:IMVT) from Peer Perform to Outperfor

Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raise